Replies to post #142595 on Cytodyn Inc (CYDY)

[kgromax]

Incorrect. The trial criteria have been organized and worded by Cytodyn in a very smart way. Important things hard to catch there in my opinion. I will explain tomorrow where is the trick. Based on the US ICU research paper, it does exclude a lot of ICU patients. More than half of them.

This kills the thesis that Leronlimab may be most useful for the most critical patients. It can’t because these patients have been excluded from the Cytodyn trial. And it kills any hope that the trial placebo mortality could approach ICU mortality. It can’t, Cytodyn has removed all the high-risk cases. And added all the non-ICU cases (severes mostly) which will drastically lower the placebo mortality rate.

This is in my opinion very bad for Cytodyn.